★ Breakthrough Medical Research • 15 Landmark Multi-Trial Guides • 6,280 Indexed Studies

Gut Health, Pain Relief, Dermatology & Autoimmune Trials — Clinical Trial Breakdowns & PubMed Evidence

Q: Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

Q: How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Q: Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

Q: How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.

Pharmacokinetic crossover trials on GelShield Extended-Release Metformin gut tolerability, topical Diclofenac patch RCTs for targeted joint relief without GI bleeding, and Phase 3 biologic clearance trials in psoriasis and autoimmune disease. Explore 546 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.

★ #1 Lead Breakthrough Study • NEJM SURMOUNT-1 (176 Weeks) N = 1,032 Adults • p < 0.001

Once-Weekly Tirzepatide Cuts Type 2 Diabetes Progression by 94% Over 3 Years—With a 22.9% Sustained Weight Reduction

The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).

Read the Full Breakthrough Breakdown → Jump to All 15 Landmark Breakthroughs ↓

Inside the Clinical Evidence Lab: Our research desk audits 6,280 human trials from NEJM, The Lancet, JAMA, and NCBI PubMed—reporting true Absolute Risk Reduction (ARR) and sample sizes (N) without pharma spin.

3. All Indexed Clinical Studies (546)

Gut, Pain & Autoimmune — Clinical Trials & Study Reports (546)

Page 19 of 19 • Sorted by Participant Sample Size (N)

Peer-Reviewed Journal (Clinical Trials) LANCET-552785061

The Lancet (Clinical Trials): [Comment] Faster troponin, same time in the emergency department: what is next for acute coronary syndrome assessment?

Emergency department overcrowding and access block are now among the most consequential patient-safety problems facing acute hospitals globally.1 The associated harm is measurable, dose-dependent, and has no clearly safe threshold beyond approximately 5 h.2 Pa

The Lancet • 2026-10-29 Read Study

FDA Safety Alert & Drug Recall FDARECALL-D-0084-2027

FDA Drug Recall Alert (Class I): Glutathione Injection (Glutathione-L, Ascorbic Acid, Sodium Hydroxide, Bacteriostatic Water), 200 mg

Reason for Recall (Class I): Microbial Contamination of Sterile Products

openFDA Drug Enforcement & Recall Registry • 2026-10-28 Read Study

Journal Watch & Cohort Study LANCET-2824242815

Can This Approach Help? Inside the Latest Research on [Comment] Preserving the uterus: an effective dual therapy to avoid

Heavy menstrual bleeding is a challenging condition that, when refractory to conventional treatment, frequently culminates in hysterectomy. Endometrial ablation offers an effective, uterus-sparing alternative for women who do not desire future childbearing, wi

The Lancet • 2026-10-21 Read Study

Randomized Controlled Trial N = 160

Can This Approach Help? Inside the Latest Research on Effect of Hypericum Perforatum Oil on Prevention Ecchymosis and Pain Associated

Low molecular weight heparin is a drug with anticoagulant and antithrombotic effects. This drug is frequently administered subcutaneously to patients by nurses. Complications such as pain, ecchymosis and hematoma may commonly occur at the i

ClinicalTrials.gov Registry (NIH NLM) • 2023-06-15 Read Study

Randomized Controlled Trial N = 119

Can This Approach Help? Inside the Latest Research on Adductor Canal Blocks With Bupivacaine and Magnesium After Same-day Discharge

The purpose of this study is to determine whether the addition of magnesium to bupivacaine for the post-operative adductor canal blocks (ACB) can decrease opioid consumption and improve pain management for patients after same-day discharge

ClinicalTrials.gov Registry (NIH NLM) • 2021-05-29 Read Study

Randomized Controlled Trial N = 30

Can This Approach Help? Inside the Latest Research on Myofascial Trigger Points Release With Shockwave Therapy on Pain and Function of

Background: shoulder-hand syndrome is considered a significant reason for the reduction of upper limb functions after stroke. Purpose: To investigate the influence of Myofascial Trigger Points (MTrPs) release and shockwave therapy on pain a

ClinicalTrials.gov Registry (NIH NLM) • 2020-01-30 Read Study

Evidence Methodology, PubMed Verification & YMYL Standards

Frequently Asked Questions About dotMD Clinical Trial Breakdowns

Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.